Arecor Ltd has hailed the successful completion of a phase I trial for its ultra-rapid acting insulin for diabetics, which it said had a “favourable profile” when compared with standard treatments.
In an upbeat statement on Thursday, the private biotech company said that its candidate, AT247, had finished a phase I double-blind, randomised study at The Medical University of Graz and Joanneum Research in Austria, in which it was measured against two other insulins on the market, NovoRapid and Fiasp.
Complete results from this study have been submitted for publication at “a major diabetes conference” in 2020.
Sarah Howell, chief executive officer of Arecor, called the study's completion “an important step” for the company’s goal to improve treatment and healthcare outcomes for people living with Type I diabetes.
“With AT247’s favourable profile over current treatments, we believe that our products have the potential to advance the diabetic treatment landscape," Howell said, noting that full data from the phase I study will be reported "in due course".
AT247 is the first drug that the ex-Unilever spinout Arecor has taken through clinical trials, as it moves away from big pharma contracts to developing its own portfolio.
Working to improve an existing treatment - insulin - gives Arecor the chance to fast-track the development process, since it has already been proven to work.
Howells said in November that Arecor expects a “very quick phase II study” to begin within the next calendar year, before it moves AT247 into phase III.